Could a common antidepressant supercharge cancer immunotherapy?
NCT ID NCT07174947
First seen Sep 30, 2025 · Last updated May 24, 2026 · Updated 34 times
Summary
This study tests whether adding the antidepressant fluoxetine (Prozac) to standard immunotherapy can help control tumors better in people with advanced liver or gallbladder cancer who also have depression or anxiety. About 240 participants will be randomly assigned to receive immunotherapy alone or with fluoxetine. The goal is to see if the combination improves tumor shrinkage, survival, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOBILIARY MALIGNANCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, 325000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.